, Diana Miao 2, 3 , Eliezer Van Allen 2, 3 , David E. Root 3 , Arlene H. Sharpe 5, 8 , John G. Doench 3 & W. Nicholas Haining 1, 3, 5 The notable clinical success of cancer immunotherapy using checkpoint blockade suggests that it is likely to form the foundation of curative therapy for many malignancies 1, 2 . However, checkpoint blockade does not achieve sustained clinical response in most patients 3 and additional immunotherapeutic strategies are therefore needed.
A small number of genes, such as PD-L1, that enable tumours to evade the immune system have been discovered and are the focus of intense clinical development efforts [4] [5] [6] [7] . Although cancer cells could, in theory, express many more genes that regulate their response or resistance to tumour immunity, strategies to systematically discover such genes are lacking.
Loss-of-function genetic screens have increasingly been used to study the functional consequences of gene deletion in tumour cells 8, 9 . These approaches include pooled genetic screens using CRISPR-Cas9-mediated genome editing that simultaneously test the role of a large number of genes on tumour cell growth, viability or drug resistance 10 . However, these screens have not been used to directly evaluate the role of tumour immunity 11, 12 .
Here we use a pooled loss-of-function in vivo genetic screening approach that uses CRISPR-Cas9 genome editing to discover genes that increase sensitivity or cause resistance to immunotherapy in a mouse transplantable tumour model.
In vivo genetic screen recovers immune evasion genes
We developed a pooled genetic screening approach to identify genes that increase or decrease the fitness of tumour cells growing in vivo in animals treated with immunotherapy (Fig. 1a) . First, we engineered the B16 melanoma cell line to express Cas9 (Extended Data Fig. 1a ) and confirmed efficient DNA editing using small guide RNAs (sgRNAs) targeting PD-L1 (Extended Data Fig. 1g, top) . Next, we created a library of lentiviral vectors encoding 9,872 sgRNAs targeting 2,368 genes from relevant functional classes that were expressed at detectable levels in the tumour cell line (Extended Data Fig. 1b) . After transduction and in vitro passage to allow gene editing to take place, we transplanted the tumour cells into animals that were then treated with either a granulocytemacrophage colony-stimulating factor (GM-CSF)-secreting, irradiated tumour cell vaccine (GVAX) or GVAX combined with PD-1 blockade using a monoclonal antibody against PD-1 to generate an adaptive immune response sufficient to apply immune-selective pressure on the tumour cells [13] [14] [15] ( Fig. 1b and Extended Data Fig. 1c ). In parallel, we transplanted the library-transduced tumour cells into Tcra −/− mice, which lack CD4 + and CD8 + T cells and were therefore unable to apply adaptive immune-selective pressure on the tumours. After 12-14 days, we collected the tumours (Fig. 1b and Extended Data Fig. 1c ) and compared the library representation in tumours from immunotherapy-treated wild-type animals to tumours growing in Tcra −/− mice (Extended Data Fig. 1d-f, h) .
Inspection of the list of genes targeted by sgRNAs that are depleted from tumours treated with immunotherapy revealed the known immune evasion molecule PD-L1, indicating that loss of PD-L1 increased the sensitivity of tumour cells to immune attack. sgRNAs targeting PD-L1 were not depleted from tumours in Tcra −/− mice relative to cells growing in vitro, presumably owing to the absence of T-cell-mediated selective pressure (Fig. 1c ), but were significantly depleted from tumours in wild-type mice treated with GVAX relative to Tcra −/− mice (false discovery rate (FDR) = 0.004). However, the depletion of PD-L1-targeting sgRNAs observed in GVAX-treated tumours was not found in tumours treated with GVAX and anti-PD-1, suggesting that loss of PD-L1 does not confer a selective disadvantage to tumours when PD-L1-PD-1 interactions are blocked (Fig. 1c) .
We also found that sgRNAs targeting CD47, which enables immune evasion by impairing engulfment of tumours cells by phagocytes 6 , were markedly depleted in tumours treated with either GVAX or with GVAX and PD-1 blockade (FDR = 0.005, FDR = 0.002, respectively) article reSearcH ( Fig. 1d and Extended Data Fig. 1g, bottom) . To confirm that CD47-null tumours were more susceptible to GVAX and PD-1 blockade, we generated CD47-null B16 melanoma cells using transient transfection of a Cas9-sgRNA plasmid (Extended Data Fig. 2a ) and found that loss of CD47 significantly improved control of tumour growth mediated by GVAX and anti-PD-1 immunotherapy (Extended Data Fig. 2b , P < 0.01). Therefore, in vivo genetic screening recovered genes known to confer immune evasion properties on cancer cells.
Defects in the IFNγ pathway induces resistance
We next analysed genes that, when deleted, become significantly enriched in immunotherapy-treated tumours, as these might represent resistance mechanisms. We observed that sgRNAs targeting five genes required for sensing and signalling through the IFNγ pathway (Stat1, Jak1, Ifngr2, Ifngr1 and Jak2) were significantly enriched in immunotherapy-treated mice ( Fig. 1e ; FDR < 0.09). We confirmed this finding in an in vivo competitive assay that compared the relative growth of mixtures of isogenic Stat1-null or control B16 cells in animals treated with immunotherapy (Fig. 1f) . In wild-type mice treated with GVAX and anti-PD-1 immunotherapy, the relative proportion of Stat1-null cells increased significantly ( Fig. 1g, h ; P < 0.01, Student's t-test), suggesting that Stat1-null cells have a marked growth advantage over wild-type tumour cells when under immune attack. Similar results were obtained for Jak1-null and Ifngr1-null cells (Fig. 1h) . Consistent with this finding, tumours deficient in Stat1 or Ifngr1 (Extended Data  Fig. 4a , c) grew significantly faster than wild-type tumours when treated with immunotherapy (Extended Data Fig. 2c ; P < 0.05, Student's t-test). Similar trends were observed for Jak1-null tumours (Extended Data Fig. 2c) Fig. 4b, d ) had significantly larger tumours and shorter survival than mice with wild-type tumours when treated with PD-1 blockade (Extended Data Fig. 2d ; P < 0.05, Student's t-test; P < 0.0001, log-rank test). Therefore, the efficacy of immunotherapy in both melanoma models depends in part on the sensing of IFNγ by tumour cells.
We next sought to determine why IFNγ -pathway mutant tumours were resistant to immunotherapy. IFNγ -pathway-deficient B16 tumour cells had a significant growth advantage over wild-type tumour cells when exposed to IFNγ or IFNβ (Extended Data Fig. 2e , P < 0.001, Student's t-test). In addition, tumour cells deficient in Stat1, Jak1 or Ifngr1 failed to upregulate MHC-I presentation molecules after stimulation with IFNγ (Extended Data Fig. 2f ). Indeed, co-culture of wild-type and Stat1-null tumour cells that had been engineered to express the model antigen ovalbumin (OVA) with antigen-specific OT-I CD8 + T cells resulted in a significantly larger fraction of Stat1-null B16 cells surviving relative to wild-type B16 cells (Extended Data Fig. 2g ; P < 0.001, Student's t-test), suggesting decreased sensitivity of Stat1-null tumour cells to the effects of cytotoxic T cells. Thus the screening platform recovered both known immune evasion molecules and mechanisms of resistance to immunotherapy.
Gene targets that increase efficacy of immunotherapy
Among the 50 most-depleted genes in immunotherapy-treated mice (all with an FDR < 0.08), we identified four prominent biological pathways. sgRNAs targeting genes involved in: (i) TNF signalling/NF-κ B activation; (ii) antigen processing and presentation; (iii) inhibition of kinase signalling; or (iv) the ubiquitin-proteasome pathway were markedly depleted in mice treated with GVAX and PD-1 blockade (Fig. 2a) relative to growth in Tcra −/− mice. In many cases, multiple members of the same pathway (for example, Erap1, Tap2, Calr) or even the same multi-protein complex (for example, Rbck1, Rnf31, Birc2) were depleted under immune selective pressure, underscoring the importance of these diverse biological pathways.
We selected representative genes from each of these four groups to validate based on their highest cumulative score as ranked by the STARS algorithm (see Methods). These genes were Ptpn2, a phosphatase involved in multiple signalling processes; H2-T23, a non-classical MHC-I gene; Ripk1, a kinase that regulates cell death and inflammation; and Stub1, an E3 ubiquitin ligase involved in the regulation of the unfolded protein response. In vivo competition assays showed that tumour cells deleted of each of the four genes were strongly selected against in wild-type animals treated with immunotherapy, but grew at equivalent rates to control tumour cells in vitro and in Tcra −/− mice ( Fig. 2b, c ; n = 8-10 mice per group). * * P < 0.01; * * * P < 0.001.
article reSearcH that loss of function of these genes renders tumour cells more sensitive to immunotherapy, but does not alter their cell growth or survival in the absence of T cells.
H2-T23 encodes Qa-1b (HLA-E in humans), a non-classical MHC molecule that binds the inhibitory receptor NKG2A on T cells and natural killer (NK) cells 16 . We confirmed that loss of function of Qa-1b enhanced the efficacy of immunotherapy by comparing the growth of H2-T23-null B16 melanoma cells (Extended Data Fig. 4g ) to control B16 tumours in mice treated with GVAX and PD-1 blockade. Immunotherapy in control tumours eradicated only 1 out of 10 tumours. By contrast, immunotherapy of H2-T23-null tumours was curative in all 10 animals ( 
Loss of Ptpn2 sensitizes tumours to immunotherapy
We next focused on Ptpn2, and confirmed that loss of Ptpn2 sensitized tumours to immunotherapy in in vivo competition assays with two additional sgRNAs (Extended Data Fig. 3a -c; P < 0.01, Student's t-test; all sgRNAs shown). Ptpn2-null B16 tumours were significantly more sensitive to immunotherapy ( Enforced expression of PTPN2 in Ptpn2-null tumour cells (that is, Ptpn2 rescue) abrogated the sensitivity to immunotherapy in vivo ( Fig. 3c, d ; P < 0.05, Student's t-test), suggesting that off-target effects of gene editing were not likely to be the cause of the increased sensitivity. Moreover, overexpression of Ptpn2 in control B16 tumour cells (that is, Ptpn2 overexpression) led to an outgrowth of tumour cells in immunotherapy-treated mice ( Fig. 3c, d ; P < 0.001, Student's t-test), indicating that increased Ptpn2 expression renders tumour cells resistant to the effect of immunotherapy.
To determine whether PTPN2 amplification was associated with immunotherapy resistance in human cancer, we examined exomesequencing data from patients treated with blockade of PD-1, PD-L1 or CTLA-4. PTPN2 amplification occurred in 20 patients, but the majority of these events were chromosomal or arm-level amplifications. Focal amplification occurred in only two patients, a number too small to conclusively determine whether PTPN2 amplification results in a mechanism of resistance (Extended Data Fig. 6 ).
Ptpn2 loss increases antigen presentation by tumours
To identify the mechanisms by which loss of Ptpn2 enhanced the efficacy of immunotherapy, we compared the composition of immune cell subsets in the tumour microenvironment of control and Ptpn2-null 
In vitro ; n = 10 mice per group; representative of two independent experiments. * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001. + T cells and γ δ + T cells ( Fig. 4a ; P < 0.05, Student's t-test). We confirmed this observation with immunohistochemistry staining and found a threefold increase in the number of CD8α + cells, which diffusely infiltrated Ptpn2-deficient tumours ( Fig. 4b ; P < 0.01, Student's t-test) treated with immunotherapy. Further flow cytometry analysis revealed that Ptpn2-null tumours contained an increased fraction of CD8 + T cells expressing granzyme B ( Fig. 4c ; P < 0.01, Student's t-test). Thus, Ptpn2 loss increased the number of activated, cytotoxic CD8 + T cells in tumours. We reasoned that the increase in number of cytotoxic CD8 + T cells in Ptpn2-null tumours could be due to improved recognition of tumour cells through increased antigen presentation. To test this, we expressed full-length OVA in Ptpn2-null or control B16 cells. Staining with a monoclonal antibody specific to the SIINFEKL epitope from OVA in the context of H2K(b) was significantly higher in Ptpn2-null cells, suggesting that loss of Ptpn2 increased the levels of antigen-loaded MHC-I on the surface of tumour cells ( Fig. 4d ; P < 0.001, Student's t-test). Additionally, Ptpn2-deficient cells had increased total MHC-I after treatment with IFNγ compared with control cells (Extended Data Fig. 9a ; P < 0.01, Student's t-test).
To test whether loss of Ptpn2 made tumour cells more recognizable to T cells, we cultured OVA-expressing Ptpn2-null or control cells with 
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OT-I CD8 + T cells that recognize the SIINFEKL epitope. T cells cultured with Ptpn2-null OVA-B16 cells were significantly more activated as measured by intracellular IFNγ and TNF staining ( Fig. 4e ; P < 0.001, Student's t-test). To test whether Ptpn2-null tumour cells were more sensitive to the presence of T cells, we co-cultured mixed populations of OVA-expressing Ptpn2-null or wild-type B16 cells with antigen-specific CD8 + T cells for six days. Ptpn2-deficient tumour cells were preferentially depleted from the co-culture ( Fig. 4f; P < 0.05, Student's t-test) . Thus, loss of Ptpn2 in tumour cells increased antigen presentation and sensitivity to cytotoxic CD8 + T cells.
Loss of Ptpn2 increases IFNγ sensing by tumour cells
Ptpn2 negatively regulates IFNγ signalling by dephosphorylating JAK1 and STAT1 (refs 17, 18) . We tested whether Ptpn2 loss sensitized tumours to immunotherapy by increasing IFNγ signalling. We first assayed STAT1 activity in Ptpn2-null cells in response to IFNγ stimulation. Ptpn2-null B16 cells showed increased phosphorylated (p-)STAT1 after treatment with IFNγ while overexpression of Ptpn2 repressed this phosphorylation (Fig. 5a ).
Transcriptional analysis of the Ptpn2-null and control B16 tumour cells exposed to IFNγ , TNF or both indicated that loss of Ptpn2 caused a marked change in the expression profile of IFNγ response genes following IFNγ exposure, but did not change gene expression in unstimulated conditions or after TNF stimulation alone ( Fig. 5b;  Supplementary Information 2) . Co-stimulation of IFNγ and TNF had a synergistic effect on Ptpn2-null cells, because IFNγ stimulation appeared to sensitize B16 cells to TNF (Extended Data Fig. 9b ). Loss of function of PTPN2 in four human tumour cell lines also increased expression of IFNγ response genes following stimulation with IFNγ ( Fig. 5c ; FDR < 0.001). Several T cell chemokines were upregulated in Ptpn2-null cells (Cxcl9, Cxcl10, Cxcl11 and Ccl5; Fig. 5b ), which might increase infiltration of T cells into tumours. Members of the antigen processing and presentation pathway, such as Tap1, Tapbp and B2m were also upregulated in Ptpn2-null cells (Fig. 5b) , consistent with our previous observation of enhanced antigen presentation in Ptpn2-deficient cells.
Cell-cycle regulators such as Cdkn1a and several genes involved in apoptosis, such as Casp4, Casp8, Ifit2, Ripk1 and Bak1, were significantly upregulated in Ptpn2-null tumour cells treated with cytokines relative to wild-type tumour cells. Consistent with this finding, exposure to IFNγ alone or in combination with IFNβ or TNF significantly reduced the growth of Ptpn2-null mouse ( Fig. 5d ; P < 0.001, Student's t-test) and human ( Fig. 5e ; P < 0.01, Student's t-test) tumour cell lines in vitro relative to wild-type tumour cells. These results demonstrate that IFNγ alone is sufficient to cause a growth disadvantage in both mouse and human tumour cells that lack Ptpn2/PTPN2.
Sensitivity of Ptpn2-null tumours depends on IFNγ
To determine whether the mechanism of increased immunotherapy sensitivity of Ptpn2-null tumour cells depends on IFNγ sensing and signalling, we generated B16 tumour cell lines in which Ptpn2 had been knocked out and Stat1, Jak1, Ifngr1 or Ifnar2 had also been knocked out (Fig. 5f ). We then tested the growth of these double-null cells relative to tumour cells lacking only Stat1, Jak1, Ifngr1 or Ifnar2 in animals treated with GVAX and anti-PD-1 immunotherapy. Loss of Ptpn2 alone was associated with a significant growth disadvantage in the presence of immunotherapy as expected (Fig. 5g, h ). However, simultaneous loss of function of any of the genes necessary for the sensing of IFNγ abolished the growth disadvantage of Ptpn2-null cells (Fig. 5g, h ; P < 0.01, Student's t-test). Loss of Ifnar2, a gene that senses type I interferon, did not abrogate the sensitivity of Ptpn2-null tumours to GVAX and anti-PD-1 immunotherapy (Fig. 5h) . This genetic epistasis experiment indicates that in tumour cells that are unable to respond to IFNγ signalling, Ptpn2 deficiency cannot sensitize tumour cells to immunotherapy. Thus, the mechanism by which Ptpn2 deficiency sensitizes tumour cells to immunotherapy is dependent on the sensing of IFNγ .
Discussion
We used pooled loss-of-function genetic screens in vivo to discover multiple genes in diverse biological processes that sensitize tumours to immunotherapy, providing a new approach for immuno-oncology target discovery. Deletion of Ptpn2 markedly increased the response of tumours to immunotherapy. Ptpn2 encodes a protein tyrosine phosphatase that regulates a range of intracellular processes, including IFNγ signalling, which it can inhibit by dephosphorylating STAT1 and JAK1 (refs 17-21) . Loss of Ptpn2 in tumour cells increased IFNγ signalling and antigen presentation to T cells, and amplified growth arrest in response to cytokines, suggesting that its therapeutic inhibition may potentiate the effect of immunotherapies that invoke an IFNγ response.
Loss of function of Qa-1b (the non-classical MHC molecule encoded by H2-T23, or HLA-E in humans) increased sensitivity of tumour cells to immune attack. The function of Qa-1b/HLA-E in tumour immunity has been unclear, because it can bind to both activating and inhibitory receptors expressed by T cells and NK cells 16, 22 , and because it has been variously reported to be associated with good or bad clinical outcomes 23, 24 . Loss of function of Qa-1b may increase the immune response to tumours by de-repression of T-or NK-cell function 25, 26 or by limiting the stimulation of CD8 + T regulatory cells 27 , either of which would make blockade of HLA-E an attractive immunotherapeutic approach.
Tumours were also sensitized to immunotherapy by deletion of Ripk1, as well as by loss of function of members of the linear ubiquitin assembly complex (LUBAC), Birc2, Rbck1 or Rnf31, that responsible for ubiquitination and stabilization of the signalling complex that includes Ripk1. Ripk1 has a complex role in the response to inflammation, including activation of NF-κ B-mediated survival pathways 28 . Strategies to alter the stability of Ripk1 in tumours may provide additional therapeutic avenues to enhance tumour immunity.
Functional genomic approaches using genome editing have to date focused on identifying genes required by tumour cells for the cancer hallmarks of growth, metastasis and drug resistance 11, 12, 29 . Our study extends this approach to interrogate the interaction of the tumour cell with the immune system. We anticipate that it can be broadly applied to systematically define genes that govern interactions between cancer cells and the immune system.
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MethOdS
In vivo CRISPR screening in B16 tumour cells. We created a Cas9-expressing version of the B16 melanoma cell line and confirmed that it could edit DNA efficiently with CRISPR using sgRNAs targeting the PD-L1 gene. For screening the B16-Cas9 cell line, we created a library of 9,992 optimized sgRNAs targeting 2,398 genes, which were selected from the Gene Ontology (GO) term categories: kinase, phosphatase, cell surface, plasma membrane, antigen processing and presentation, immune system process, and chromatin remodelling. The transcript abundance of the genes in these categories were then filtered to include only those that were expressed > RPKM(log 2 ) = 0.9. These genes were then ranked for expression in the B16 cell line using RNA-sequencing to select for the top 2,398 expressed genes. The library was divided into four sub-pools, each containing one sgRNA per gene and 100 non-targeting control sgRNAs. The four sub-pools were screened individually and sgRNAs were delivered to B16-Cas9 cells via lentiviral infection at an infection rate of 30%. Transduced B16 cells were purified using an hCD19 reporter by positive magnetic selection (Miltenyi) and then expanded in vitro before being implanted into animals. For each sub-pool, B16 cells were implanted into 10 Tcra −/− mice, 10 wild-type mice treated with GVAX, and 10 wild-type mice treated with GVAX and PD-1 blockade (see below for treatment protocols). B16 cells transduced with libraries were also grown in vitro at approximately 2,000× library coverage for the same time period as the animal experiment. Mice were euthanized 12-14 days after tumour implantation and tumour genomic DNA was prepared from whole tumour tissue using the Qiagen DNA Blood Midi kit. PCR was used to amplify the sgRNA region and sequencing to determine sgRNA abundance was performed on an Illumina HiSeq. Significantly enriched or depleted sgRNAs from any comparison of conditions were identified using the STARS algorithm 31 . Cell lines. B16F10 melanoma and B16-GM-CSF were a gift from G. Dranoff. Braf/ Pten melanoma were from D.E.F. MC38 colon carcinoma cells was a gift from A. Sharpe. A375 melanoma, A549 lung carcinoma and HT-29 colon carcinoma cells were purchased from ATCC. MelJuSo melanoma cells was a gift from the Cancer Cell Line Encyclopedia (Broad Institute). B16, MC38, A549 and HT-29 cells were all grown in DMEM (Gibco) with 10% fetal bovine serum (Gemini biosciences) and antibiotics. A375 and MelJuSo cells were grown in RPMI 1640 (Gibco) with 10% fetal bovine serum and antibiotics. All cell lines were subject to periodic testing for mycoplasma using the LookOut Mycoplasma PCR detection kit (Sigma). Animal treatment and tumour challenges. The designs of these animal studies and procedures were approved by the Dana-Farber Cancer Institute IACUC committee. Dana-Farber Cancer Institute's specific-pathogen free facility was used for the housing and care of all mice. Seven-week old wild-type female C57BL/6J mice were obtained from Jackson laboratories. A colony of B6.129S2-Tcra tm1Mom /J (Tcra −/− ) T cell-deficient mice were bred on site. Mice were age-matched to be 7-12 weeks old at the time of tumour inoculation. For screening, 2.0 × 10 6 librarytransduced B16-Cas9 cells resuspended in Hanks Balanced Salt Solution (Gibco) were mixed 1:1 by volume with Matrigel (Corning) and subcutaneously injected into the right flank on day 0. Mice were vaccinated with 1.0 × 10 6 GM-CSFsecreting B16 (GVAX) cells (provided by G. Dranoff) that had been irradiated with 3,500 Gy on days 1 and 4 to elicit an anti-tumour immune response. Subsequently, mice were treated with 100 μ g of rat monoclonal anti-PD1 (clone: 29F.1A12) on days 9 and 12 via intraperitoneal injection. For validation assays, 1.0 × 10 6 tumour cells were subcutaneously injected into the right flank without Matrigel. Tumours were measured every three days beginning on day 6 after challenge until time of death. Death was defined as the point at which a progressively growing tumour reached 2.0 cm in the longest dimension. Measurements were taken manually by collecting the longest dimension (length) and the longest perpendicular dimension (width). Tumour volume was estimated with the formula: (L × W 2 ) / 2. CO 2 inhalation was used to euthanize mice on the day of euthanasia. Optimal group sizes were determined empirically. Researchers were not blinded to group identity and randomization of animal groups was done when appropriate. Creation of CRISPR-edited tumour cell lines. Transient transfection of the Cas9-sgRNA plasmid (pX459, Addgene) was used to edit B16 and Braf/Pten melanoma cell lines. pX459 was digested with the enzyme Bpil (Thermo Fisher Scientific) as per the manufacturer's instructions and sgRNA oligos were cloned into the plasmid using standard molecular cloning. For B16 cells, 5 × 10 5 cells were plated in a well of a six-well plate and were transfected the following day using 2 μ g of pX459 plasmid DNA and Turbofect (3:1 ratio, Thermo Fisher Scientific). After 24 h of transfection, transfectants were selected in puromycin (6 μ g ml −1 , Thermo Fisher Scientific). For Braf/Pten melanoma cells, 5 × 10 5 cells were plated in a well of a six-well plate and were transfected the following day using 4 μ g of pX459 plasmid DNA and Turbofect (3:1 ratio). After selection, cells were grown for 14 days in vitro before being implanted into mice. In vivo competition assays. B16 cells were engineered to express GFP or tdTomato by lentiviral transduction to differentiate populations. Cas9-target sgRNAtransfected cells and Cas9-control sgRNA-transfected cells were mixed and then grown for at least two passages in vitro before implantation into mice. Mixes were analysed by flow cytometry on the day of tumour inoculation. Mice were euthanized 15-21 days after tumour inoculation for tumour collection. Tumours were macerated on ice and incubated in collagenase P (2 mg ml −1 , Sigma-Aldrich) and DNase I (50 μ g ml −1 , Sigma-Aldrich) supplemented DMEM for 10 min at 37 °C. After incubation, tumour cells were passed through 70-μ m filters to remove undigested tumour. Tumour cells were washed with ice-cold MACS medium and stained with Near-IR Live/Dead (1:1,000, BD Biosciences) for 10 min on ice. Tumour cells were then washed and resuspended in ice-cold PBS with 2% FBS. An Accuri C6 flow cytometry system (BD Biosiences) was used to analyse final GFP:tdTomato tumour cell ratios. In vitro cytokine stimulations. Differentially labelled B16 cells were plated in 12-well plates in DMEM + 10% FBS containing the indicated combinations of cytokines: TNFα (10 ng ml , Sigma-Aldrich) for 10 min, and pipetted into a single-cell suspension. After filtering through a 70-μ m filter, cells were blocked with anti-mouse CD16/32 antibody (BioLegend) and stained with indicated antibodies for 30 min on ice. Dead cells were excluded using Aqua Live/ Dead (1:1,000, ThermoFisher Scientific) added concurrently with surface antibodies. After washing, cells were fixed with Foxp3/Transcription Factor Staining Buffer Set (eBiosciences) as per manufacturer's instructions, blocked with mouse and rat serum, then stained with intracellular antibodies. Spherotech AccuCount Fluorescent particles were added for cell quantification before analysis on an LSR Fortessa using single-colour compensation controls and fluorescence-minus-one thresholds to set gate margins. Comparisons between groups were performed using Student's t-tests. Flow cytometry analysis of B16 tumour cells. B16 cells were trypsinized and washed in PBS + 2% FBS, stained with antibodies against cell surface proteins as per the manufacturer's instructions and then analysed on an Accuri C6 flow cytometry system. Restimulation of T cells on B16 tumour cells. OT-I T cells were isolated from the spleens of OT-I T cell receptor transgenic mice using the CD8a + T cell isolation mouse kit (Miltenyi), as per manufacturer's instructions. Purified OT-I T cells were then stimulated in 24-well plates with plate-bound anti-mouse CD3ε (2 μ g ml −1 , BD Biosciences), soluble anti-mouse CD28 (2 μ g ml −1 , BD Biosciences) and recombinant human IL-2 (100 U ml −1 , DFCI supply centre). After 48 h, activated OT-I T cells were transferred into fresh media containing recombinant human IL-2 and allowed to expand for 5-7 days. For restimulation, 1 × 10 5 OVAexpressing Ptpn2-null or control sgRNA-transfected B16 tumour cells were first plated in 24-well plates and stimulated with recombinant mouse IFNγ overnight to induce ovalbumin surface expression. 1 × 10 6 pre-activated OT-I T cells were then added to the wells on the next day and co-cultured with the B16 tumour cells for 2-3 h. Subsequently, 1× brefeldin (eBiosciences) was added to the cultures for 4 h to inhibit intracellular protein transport. Afterward, OT-I T cells were collected from each well, stained for surface markers and then fixed with Foxp3/ Transcription Factor Staining Buffer Set (eBiosciences) as per the manufacturer's instructions. Intracellular cytokine staining was then performed before analysis on an LSR Fortessa. RNA-sequencing analysis of tumour cells. Ptpn2-null or control sgRNAtransfected B16 cells were stimulated with IFNγ (100 ng ml −1 , Cell Signaling Technology), TNFα (10 ng ml −1 , Peprotech) or both for 48 h. RNA was extracted from cell pellets using the Qiagen RNeasy Mini kit according to the manufacturer's instructions. First-strand Illumina-barcoded libraries were generated using the NEB RNA Ultra Directional kit according to the manufacturer's instructions, including a 12-cycle PCR enrichment. Libraries were sequenced on an Illumina NextSeq 500 instrument using paired-end 37 bp reads. Data were trimmed for quality using the Trimmomatic pipeline with the following parameters: LEADING:15 TRAILING:15 SLIDINGWINDOW:4:15 MINLEN:16. Data were aligned to mouse reference genome mm10 using Bowtie2. HTSeq was used to map aligned reads article reSearcH to genes and to generate a gene count matrix. Normalized counts and differential expression analysis was performed using the DESeq2 R package. We performed gene set enrichment analysis, as described previously 32, 33 . Western blotting. Whole cell lysates were prepared in lysis buffer (60 mM Tris HCl, 2% SDS, 10% glycerol, complete EDTA-free protease inhibitor (Roche)) and 500 U ml −1 benzonase nuclease (Novagen). Samples were boiled at 100 °C and clarified by centrifugation. Protein concentration was measured with a BCA protein assay kit (Pierce). Subsequently, 50-150 μ g of protein was loaded on 4-12% Bolt Bis-Tris Plus gels (Life Technologies) in MES buffer (Life Technologies). Protein was transferred to 0.45-μ m nitrocellulose membranes (Bio-Rad). Membranes were blocked in Tris-buffered saline plus 0.1% Tween 20 (TBS-T) containing 5% nonfat dry milk for 1 h at room temperature followed by overnight incubation with primary antibody at 4 °C. Membranes were washed with TBS-T and incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. HRP was activated with Supersignal West Dura Extended Duration Substrate (Pierce) and visualized with a chemiluminscent detection system using Fuji ImageQuant LAS4000 (GE Healthcare Life Sciences). Blots were then analysed using ImageJ and Adobe Photoshop software. Immunohistochemistry. Whole B16 tumours were fixed for 24 h in 10% neutral-buffered formalin and then permeabilized in 70% ethanol overnight. Fixed tissue was subsequently embedded into paraffin, sectioned and then mounted onto slides for staining against mouse CD8α (eBiosciences, 14-0808-82). Slides were imaged on a Leica Scanscope XT and analysed using Aperio software. Exome-sequencing analysis. All human studies were conducted in accordance with the Declaration of Helsinki and approved by the Dana-Farber Cancer Institute Institutional Review Board (Protocols 11-104, 02-180, 09-472, 02-021, 15-330). Informed consent was obtained from all subjects. Electronic medical charts were reviewed to assess best response by RECIST (version 1.1), duration of progressionfree survival, duration of overall survival, patient demographic characteristics and other relevant clinical details (for example, smoking history). Patients from the Dana-Farber Cancer Institute with metastatic bladder cancer, head and neck squamous cell carcinoma, lung cancer and melanoma treated with anti-PD-1, anti-PD-L1, anti-CTLA-4, or a combination of these therapies were identified, and pre-treatment tumour tissue and matched germline blood were obtained for exome sequencing. Copy-number alterations were called using a circular binary segmentation method 34 . Called copy-number ratio was corrected for tumour purity and ploidy using ABSOLUTE. A threshold of log 2 (copy ratio) > 0.5 was used to call amplifications. The amplified region containing PTPN2 for each tumour that was shown to be amplified was manually examined to determine whether the amplification was part of a chromosome-level, arm-level or focal amplification event.
Patients were stratified by clinical benefit using the metric published previously 35 . In brief, patients with clinical benefit had a complete response or partial response by RECIST (version 1.1) or stable disease with overall survival exceeding one year. Patients with no clinical benefit had progressive disease as best response by RECIST or stable disease with overall survival less than one year. A third group of patients with PD but overall survival exceeding two years were called long-term survival with no clinical benefit. Antibodies. For western blotting, primary antibodies against STAT1 (9172, Cell Signaling), JAK1 (3332 and 3344 (clone 6G4), Cell Signaling), p-STAT1 (Tyr701) (clone D4A7, Cell Signaling), β -actin (8227, Abcam), TC-TPT (PTPN2) (180764, Abcam) and Flag (clone M2, Sigma-Aldrich) were used. Peroxidase-conjugated secondary antibodies against rabbit IgG (111-035-046) and mouse IgG (115-035-174) were purchased from Jackson Laboratories. 
